Liver Stiffness And Serum Fibrosis Biomarker Variations After Daas Treatment: Predictive Role In Hepatocellular Carcinoma Development In In Cirrhotic Patients

Introduction: Direct acting antivirals (DAAs) are an effective treatment in HCV patients since SVR is achieved in more than 90% of the patients after 12–24 months. However, HepatoCellular Carcinoma (HCC) development risk does not seem to reduce in SVR patients after DAA-treatments. Recently, it has been suggested that liver stiffness measurement (LSM) by Fibroscan [Echosens®] can predict the HCC risk in liver cirrhosis patients.